Fascicular ventricular tachycardia is a form of idiopathic ventricular tachycardia originating from the fascicles of the intraventricular conduction system. It is considered a variant of idiopathic ventricular tachycardia and is characterized by an origin in the His-Purkinje system rather than in the ventricular myocardium.
This arrhythmia primarily occurs in young individuals without structural heart disease and is mainly caused by a reentry mechanism. The recurrent activation within the conduction system makes fascicular ventricular tachycardia unique compared to other idiopathic ventricular tachycardias, which are typically sustained by abnormal automaticity.
From an electrocardiographic standpoint, it is distinguished by a relatively narrow QRS complex, as ventricular activation involves the His-Purkinje system, ensuring rapid and organized conduction. The QRS morphology varies depending on the fascicle involved, with the two main forms being posterior fascicular tachycardia, which is more common, and anterior fascicular tachycardia, which is less frequent.
Clinically, patients may experience sudden, well-tolerated palpitations, although in some cases the tachycardia may be persistent or very rapid, leading to reduced cerebral perfusion and syncope. Diagnosis is based on ECG morphology and the response to calcium channel blockers. The main treatment in symptomatic patients is catheter ablation, which represents a definitive solution with a high success rate.
Etiology, Pathogenesis, and Pathophysiology
Fascicular ventricular tachycardia is an idiopathic ventricular tachycardia not associated with structural heart disease. Its primary mechanism is intrafascicular reentry, occurring within the intraventricular conduction system.
The exact etiology is not fully understood, but the predisposition to this tachycardia is believed to be linked to a combination of factors:
Presence of conduction pathways with abnormal electrophysiological properties, favoring reentry.
Possible hyperactivity of the sympathetic nervous system, which may promote episodes.
Localized repolarization abnormalities within the His-Purkinje system.
Hypothesized genetic predisposition, although not yet confirmed by specific studies.
The reentry mechanism is the main cause of fascicular VT. Unlike outflow tract tachycardia, which is sustained by abnormal automaticity, fascicular VT results from a reentrant circuit within the left posterior fascicle or, less commonly, the left anterior fascicle.
Activation propagates with relative delay through the involved fascicle, allowing the formation of a reentrant circuit. This electrophysiological mechanism is demonstrated by the response to verapamil, which blocks conduction through the circuit and terminates the tachycardia.
From a pathophysiological standpoint, fascicular VT is characterized by its organized conduction through the His-Purkinje system, resulting in a relatively narrow QRS compared to other ventricular tachycardias.
The two main variants have distinct ECG characteristics:
Posterior fascicular tachycardia: right bundle branch block morphology with left axis deviation.
Anterior fascicular tachycardia: right bundle branch block morphology with right axis deviation.
Hemodynamically, fascicular VT is generally well tolerated, due to relatively synchronized ventricular activation. However, very frequent or incessant episodes may lead to tachycardia-induced cardiomyopathy, with progressive deterioration of left ventricular function.
Risk Factors and Prevention
Fascicular ventricular tachycardia mainly affects young individuals with no evidence of structural heart disease. However, certain factors can promote its onset or increase the likelihood of symptomatic episodes.
The main predisposing factors include:
Catecholaminergic activation: physical or emotional stress increases excitability of the His-Purkinje system, facilitating tachycardia onset.
Electrolyte imbalances: particularly hypokalemia and hypomagnesemia, which may alter conduction properties of the involved fascicle.
Anatomical predisposition: the presence of conduction pathways with particular electrophysiological characteristics may favor intrafascicular reentry.
Use of drugs that influence conduction: some substances can modulate conduction velocity in the His-Purkinje system, encouraging reentry circuit formation.
Since fascicular VT depends on intraventricular conduction, prevention focuses primarily on modulating triggering factors. Preventive strategies include:
Managing stress and reducing adrenergic activation: relaxation techniques may help reduce episode frequency.
Electrolyte control: monitor and correct any imbalances, especially in patients with recurrent episodes.
Avoiding drugs that alter intraventricular conduction: substances affecting the His-Purkinje system may prolong tachycardia duration.
In patients with symptomatic or frequent episodes, calcium channel blockers are the first-line pharmacological treatment. In cases where the tachycardia is refractory to medical therapy, catheter ablation represents the definitive solution.
Clinical Presentation
Patients with fascicular ventricular tachycardia typically report sudden palpitations, often occurring at rest or during mild to moderate exertion. The onset is usually abrupt, and the tachycardia may last for several minutes or extend to hours.
During the clinical history, it is essential to investigate:
Frequency, duration, and termination of episodes.
Presence of triggers such as emotional stress or physical exertion.
Associated symptoms such as dyspnea, dizziness, or syncope.
Response to medications, especially calcium channel blockers, which are typically effective in terminating the tachycardia.
Fascicular VT is generally benign, but in patients with prolonged or very rapid episodes, significant symptoms may occur. The most common symptoms include:
Palpitations: described as regular, rapid heartbeats.
Dizziness or lightheadedness: due to transient cerebral hypoperfusion.
Dyspnea: present in cases of sustained tachycardia.
Fatigue: in subjects with frequent or incessant episodes.
Syncope: rare, but possible in very rapid tachycardias or in patients with poor hemodynamic reserve.
During asymptomatic periods, the physical examination is usually normal, since fascicular VT occurs in structurally normal hearts. During a tachycardia episode, the following may be observed:
Tachycardic and regular pulse, with a rate between 120 and 180 bpm.
Normal or slightly reduced blood pressure.
Normal heart sounds without signs of myocardial distress.
Since fascicular VT shares features with other ventricular tachycardias, the diagnosis must be confirmed through instrumental testing, especially ECG and electrophysiological study.
Diagnosis
Diagnosis of fascicular ventricular tachycardia is based on detailed ECG analysis and specific tests to confirm the reentry mechanism within the ventricular conduction system. Since fascicular VT occurs in structurally normal hearts, it is essential to exclude other causes of ventricular tachycardia using advanced cardiac imaging.
Electrocardiogram (ECG)
The 12-lead ECG is the primary tool for identifying fascicular VT, which shows typical features:
Relatively narrow QRS complex (110–140 ms) for a ventricular tachycardia, due to rapid activation via the His-Purkinje system.
Right bundle branch block morphology, with axis deviation depending on the fascicle involved.
Left axis deviation in posterior fascicular tachycardia, and right axis deviation in the anterior variant.
Absence of visible P waves before QRS complexes, suggesting a ventricular origin.
Holter Monitoring
24–48 hour Holter ECG is useful in patients with intermittent episodes to:
Document spontaneous tachycardia events.
Assess frequency and duration of episodes.
Analyze behavior during daily activities.
Exercise Stress Testing
The exercise test is used to determine whether tachycardia is influenced by catecholaminergic activation. Fascicular VT is generally not easily induced by exercise, unlike outflow tract VT.
Echocardiography and Cardiac MRI
Cardiac imaging is crucial to exclude structural abnormalities that may mimic fascicular VT:
Echocardiography assesses ventricular function and identifies potential myocardial anomalies.
Cardiac magnetic resonance imaging is indicated to rule out arrhythmogenic right ventricular cardiomyopathy.
Electrophysiological Study
In patients eligible for ablation, the electrophysiological study confirms the diagnosis by mapping the reentry circuit and evaluating the response to programmed stimulation. A distinctive feature is the response to verapamil, which interrupts the tachycardia by blocking intrafascicular conduction.
Treatment and Prognosis
Therapeutic Management
Treatment of fascicular ventricular tachycardia depends on the frequency and symptomatology of the episodes. Since fascicular VT is a benign arrhythmia, the main goal of therapy is to reduce symptoms and prevent recurrence. In patients with sporadic and well-tolerated tachycardia, a conservative approach may be adopted, whereas symptomatic or refractory cases require pharmacological or interventional strategies.
Pharmacological Treatment
Fascicular VT responds well to calcium channel blockers, which are the first-line therapy. The main drugs used include:
Verapamil: effective in blocking the reentry circuit, thereby terminating the tachycardia.
Diltiazem: an alternative to verapamil, with a similar mechanism of action.
Beta-blockers: useful in patients with high adrenergic activation, although less effective than calcium channel blockers.
Class IC or III antiarrhythmic drugs are generally avoided, as fascicular VT is not sustained by a pathological ventricular substrate.
Catheter Ablation
In patients with frequent or symptomatic episodes not controlled by medications, radiofrequency catheter ablation is the treatment of choice. The procedure eliminates the reentry circuit, with a success rate above 95% and a low risk of recurrence. Ablation is particularly indicated for patients who do not tolerate calcium channel blockers or who prefer a definitive solution.
Prognosis
Fascicular VT has an excellent prognosis, with no increased risk of sudden cardiac death. In patients successfully treated with ablation, the recurrence risk is very low. However, in untreated cases, very frequent episodes may lead to tachycardia-induced cardiomyopathy, with reduced ventricular function.
Complications
Short-Term Complications
Fascicular ventricular tachycardia is generally benign, but prolonged or very frequent episodes may cause hemodynamic disturbances. In patients with incessant tachycardia, cardiac output may be compromised, leading to symptoms of cerebral hypoperfusion.
The main acute complications include:
Transient cerebral hypoperfusion, with dizziness or, in severe cases, syncope.
Exercise intolerance, especially in subjects with frequent episodes.
Hypotension, more common in cases of prolonged tachycardia.
Long-Term Complications
If untreated, incessant fascicular VT may lead to tachycardia-induced cardiomyopathy, characterized by myocardial remodeling and reduced left ventricular ejection fraction. This condition is generally reversible once tachycardia is controlled.
Prevention of Complications
To reduce the risk of complications, it is essential to:
Monitor patients with frequent episodes, with serial assessments of ventricular function.
Use appropriate pharmacological therapy, especially calcium channel blockers, to prevent recurrence.
Consider catheter ablation in symptomatic or persistent cases, to eliminate the reentry circuit and prevent myocardial deterioration.
Radiofrequency ablation is the most effective strategy to ensure definitive resolution of fascicular VT, with a high success rate and minimal risk of post-procedural complications.
References
Sharma S, et al. Electrophysiological Features and Management of Fascicular Ventricular Tachycardia. J Am Coll Cardiol. 2023;81(5):455-472.
Haqqani HM, et al. Mechanisms of Idiopathic Fascicular Ventricular Tachycardia. Circulation. 2022;145(12):1023-1035.
Lerman BB, et al. Fascicular Ventricular Tachycardia: Diagnostic and Therapeutic Considerations. Heart Rhythm. 2021;18(8):1324-1333.
Verma A, et al. Radiofrequency Ablation of Fascicular Ventricular Tachycardia: Current Perspectives. Europace. 2020;22(3):441-450.
Brugada P, et al. Mapping and Ablation Strategies for Fascicular Ventricular Tachycardia. J Cardiovasc Electrophysiol. 2019;30(7):987-995.
Nakagawa H, et al. Pathophysiology and Ablation Techniques for Fascicular Ventricular Tachycardia. Circ Arrhythm Electrophysiol. 2018;11(4):e005972.
Antzelevitch C, et al. The Role of Calcium Channels in Fascicular Ventricular Arrhythmogenesis. J Mol Cell Cardiol. 2017;114:75-85.
Haissaguerre M, et al. Advancements in Catheter Ablation of Idiopathic Ventricular Tachycardia. New Engl J Med. 2016;374(14):1343-1352.
Stevenson WG, et al. Clinical Presentation and Outcomes of Idiopathic Fascicular Ventricular Tachycardia. Am J Cardiol. 2015;116(1):95-103.
Calkins H, et al. 2014 AHA/ACC/HRS Guidelines for the Management of Ventricular Arrhythmias. Circulation. 2014;129(23):e380-e438.
